These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 34975869)

  • 1. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
    Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
    Front Immunol; 2021; 12():780145. PubMed ID: 34975869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
    Zhao Q; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.
    Pavlovic K; Carmona-Luque M; Corsi GI; Maldonado-Pérez N; Molina-Estevez FJ; Peralbo-Santaella E; Cortijo-Gutiérrez M; Justicia-Lirio P; Tristán-Manzano M; Ronco-Díaz V; Ballesteros-Ribelles A; Millán-López A; Heredia-Velázquez P; Fuster-García C; Cathomen T; Seemann SE; Gorodkin J; Martin F; Herrera C; Benabdellah K
    Front Immunol; 2024; 15():1401683. PubMed ID: 38868778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
    Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
    Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off the shelf T cell therapies for hematologic malignancies.
    McCreedy BJ; Senyukov VV; Nguyen KT
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors.
    Ueda T; Kaneko S
    Int J Hematol; 2021 Nov; 114(5):572-579. PubMed ID: 32705572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
    Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
    Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
    Badar T; Shah NN
    Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.